```
=> s (cyclosprin A or CsA)
L1       35100 (CYCLOSPRIN A OR CSA)

=> s (dimethyl sulfoxide or DMSO)
L2      164887 (DIMETHYL SULFOXIDE OR DMSO)

=> s l1 and l2
L3         590 L1 AND L2

=> s l3 and (pharmaceut? or therapeut?(3l)composition or formulation)
L4         422 L3 AND (PHARMACEUT? OR THERAPEUT?(3L) COMPOSITION OR FORMULATIO
               N)

=> s l4 and (administer? or inject?)
L5         393 L4 AND (ADMINISTER? OR INJECT?)

=> s l5 and (intraventricular or intrthecal)
L6          62 L5 AND (INTRAVENTRICULAR OR INTRTHECAL)

=> s l5 and (intra-ocular or intravestibular)
L7           3 L5 AND (INTRA-OCULAR OR INTRAVESTIBULAR)

=> dis l7 1-3 bib ab

L7   ANSWER 1 OF 3  USPATFULL
AN     2001:102825  USPATFULL
TI     Alpha 1a adrenergic receptor antagonists
IN     Patane, Michael A., Harleysville, PA, United States
       Selnick, Harold G., Ambler, PA, United States
       Bock, Mark G., Hatfield, PA, United States
PA     Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI     US 6255315         B1   20010703
AI     US 1999-458169          19991209 (9)
RLI    Division of Ser. No. US 1998-99031, filed on 17 Jun 1998, now patented,
       Pat. No. US 6037354
PRAI   US 1997-49921P      19970618 (60)
DT     Utility
FS     GRANTED
EXNAM  Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.
LREP   Walton, Kenneth R., Winokur, Melvin
CLMN   Number of Claims: 30
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 4169
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     This invention relates to certain novel compounds and derivatives
       thereof, their synthesis, and their use as alpha 1a adrenergic receptor
       antagonists. One application of these compounds is in the treatment of
       benign prostatic hyperplasia. These compounds are selective in their
       ability to relax smooth muscle tissue enriched in the alpha 1a receptor
       subtype without at the same time inducing hypotension. One such tissue
       is found surrounding the urethral lining. Therefore, one utility of the
       instant compounds is to provide acute relief to males suffering from
       benign prostatic hyperplasia, by permitting less hindered urine flow.
       Another utility of the instant compounds is provided by combination with
       a human 5-alpha relductase inhibitory compound, such that both acute and
       chronic relief from the effects of benign prostatic hyperplasia are
       achieved.

L7   ANSWER 2 OF 3  USPATFULL
AN     2001:67681  USPATFULL
TI     Oxazolidinones useful as alpha 1a adrenoceptor antagonists
IN     Nerenberg, Jennie B., Maple Glen, PA, United States
       Bock, Mark G., Hatfield, PA, United States
```

Patane, Michael A., Harleysville, PA, United States
Selnick, Harold G., Ambler, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6228870 B1 20010508
AI US 1999-437841 19991110 (9)
PRAI US 1998-107838P 19981110 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Dentz, Bernard
LREP Fitch, Catherine D., Walton, Kenneth R., Winokur, Melvin
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2099
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel hydroxymethyl- and alkoxymethyl-oxazolidinone compounds and **pharmaceutically** acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

L7 ANSWER 3 OF 3 USPATFULL
AN 2000:31428 USPATFULL
TI Alpha 1a adrenergic receptor antagonists
IN Patane, Michael A., Harleysville, PA, United States
Selnick, Harold G., Ambler, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6037354 20000314
AI US 1998-99031 19980617 (9)
PRAI US 1997-49921P 19970618 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.
LREP Winokur, Melvin, Walton, Kenneth R.
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4142
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

=> s l5 and (intravenous or intrarterial or intraparenchymal)

```
L8          296 L5 AND (INTRAVENOUS OR INTRARTERIAL OR INTRAPARENCHYMAL)

=> s l5 and (orally or rectally or nasally or dermally)
L9          267 L5 AND (ORALLY OR RECTALLY OR NASALLY OR DERMALLY)

=> s l6 and l7
L10           0 L6 AND L7

=> s l8 and l9
L11         210 L8 AND L9

=> s l6 and l11
L12          60 L6 AND L11

=> s l7 and l12
L13           0 L7 AND L12

=> s l12 and (cerebrospinal or vascular)
L14          44 L12 AND (CEREBROSPINAL OR VASCULAR)

=> s l14 and (brain or spinal cord)
L15          43 L14 AND (BRAIN OR SPINAL CORD)

=> s l15 and (adminster? or inject?(3l) patient)
L16          43 L15 AND (ADMINSTER? OR INJECT?(3L) PATIENT)

=> s l16 and (pharmceutical formulation or compositio)
L17           0 L16 AND (PHARMCEUTICAL FORMULATION OR COMPOSITIO)

=> s l16 and (pharmaceutical formulation or composition)
L18          32 L16 AND (PHARMACEUTICAL FORMULATION OR COMPOSITION)

=> s l18 and (treatment disease or condition)
L19          30 L18 AND (TREATMENT DISEASE OR CONDITION)

=> s l19 and (cerebrospinal fluid space)
L20           0 L19 AND (CEREBROSPINAL FLUID SPACE)

=> s l19 (cerebrospinal space)
MISSING OPERATOR 'L152 (CEREBROSPI'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l19 and (cerebrospinal space)
L21           0 L19 AND (CEREBROSPINAL SPACE)

=> s l19 and (cerebrospial)
L22           0 L19 AND (CEREBROSPIAL)

=> s l19 and (intra-ocular or intravestibular)
COMMAND INTERRUPTED
L23           0 L19 AND (INTRA-OCULAR OR INTRAVESTIBULAR)
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> dis l9 1-10 bib ab

L9   ANSWER 1 OF 267  USPATFULL
AN      2003:65395  USPATFULL
TI      Novel non-imidazole compounds
IN      Aslanian, Robert G., Rockaway, NJ, UNITED STATES
        Shih, Neng-Yang, North Caldwell, NJ, UNITED STATES
        Ting, Pauline C., New Providence, NJ, UNITED STATES
        Berlin, Michael Y., Flemington, NJ, UNITED STATES
```

Rosenblum, Stuart B., West Orange, NJ, UNITED STATES
McCormick, Kevin D., Edison, NJ, UNITED STATES
Tom, Wing C., Cedar Grove, NJ, UNITED STATES
Boyce, Christopher W., Flemington, NJ, UNITED STATES
Mangiaracina, Pietro, Monsey, NY, UNITED STATES
Mutahi, Mwangi W., Fords, NJ, UNITED STATES
Piwinski, John J., Clinton Township, NJ, UNITED STATES
PI US 2003045519 A1 20030306
AI US 2001-978267 A1 20011015 (9)
PRAI US 2000-240901P 20001017 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2838
AB Disclosed are novel compounds of the formula ##STR1##

Also disclosed are **pharmaceutical** compositions comprising the compounds of Formula I.

Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I.

Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H.sub.1 receptor antagonist.

L9 ANSWER 2 OF 267 USPATFULL
AN 2003:57074 USPATFULL
TI Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
IN Bach, Fritz H., Manchester-by-the-Sea, MA, UNITED STATES
Otterbein, Leo E., New Kensington, PA, UNITED STATES
Soares, Miguel P., Boston, MA, UNITED STATES
Tobiasch, Edda M., Bonn, GERMANY, FEDERAL REPUBLIC OF
Gose, Jeanne, Manchester-by-the-Sea, MA, UNITED STATES
PI US 2003039638 A1 20030227
AI US 2002-177930 A1 20020621 (10)
PRAI US 2001-300289P 20010621 (60)
US 2001-334340P 20011129 (60)
US 2001-337974P 20011207 (60)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
CLMN Number of Claims: 149
ECL Exemplary Claim: 1
DRWN 31 Drawing Page(s)
LN.CNT 3473
AB The present invention features methods for transplanting organs, tissues and individual cells. Also featured are methods for maintaining cells in vitro and for enhancing survival and/or function of cells following transplantation. The methods include the administration of carbon monoxide in an amount sufficient to enhance cell survival and/or function.

L9 ANSWER 3 OF 267 USPATFULL
AN 2003:53823 USPATFULL
TI Antirheumatic
IN Matsumoto, Saichi, Ikeda, JAPAN
Jyoyama, Hirokuni, Nara, JAPAN

Kakudo, Shinji, Kawanishi, JAPAN
Hanasaki, Kohji, Kyoto, JAPAN
Koizumi, Kenzo, Sakai, JAPAN
Sakata, Tsuneaki, Toyonaka, JAPAN
Suzuki, Ryuji, Ikoma, JAPAN
PA Shionogi & Co., Ltd., Osaka, JAPAN (non-U.S. corporation)
PI US 6525081 B1 20030225
WO 9921844 19990506
AI US 2000-530082 20000424 (9)
WO 1998-JP4774 19981022
PRAI JP 1997-292517 19971024
DT Utility
FS GRANTED
EXNAM Primary Examiner: Gerstl, Robert
LREP Wenderoth, Lind & Ponack, L.L.P.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 2111
AB A novel antirheumatic agent comprising as an active ingredient a compound of formula I: ##STR1##

or a **pharmaceutically** acceptable salt or hydrate thereof.

L9 ANSWER 4 OF 267 USPATFULL
AN 2003:45323 USPATFULL
TI Heterocyclic esters and amides
IN Li, Jia-He, Cockeysville, MD, UNITED STATES
Hamilton, Gregory S., Catonsville, MD, UNITED STATES
PI US 2003032635 A1 20030213
AI US 2002-177666 A1 20020624 (10)
RLI Continuation of Ser. No. US 2000-733043, filed on 11 Dec 2000, PENDING Division of Ser. No. US 1998-27622, filed on 23 Feb 1998, GRANTED, Pat. No. US 6200972 Continuation of Ser. No. US 1996-719947, filed on 25 Sep 1996, GRANTED, Pat. No. US 5801187
DT Utility
FS APPLICATION
LREP GUILFORD PHARMACEUTICALS C/O, FOLEY & LARDNER, 3000 K STREET, NW, WASHINGTON, DC, 20007-5143
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 886
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule heterocyclic ester and amides having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L9 ANSWER 5 OF 267 USPATFULL
AN 2003:45314 USPATFULL
TI Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
IN Mayer, Scott Christian, Bridgewater, NJ, UNITED STATES
Gundersen, Eric Gould, Hightstown, NJ, UNITED STATES
Elokdah, Hassan Mahmoud, Yardley, PA, UNITED STATES
Crandall, David LeRoy, Doylestown, PA, UNITED STATES
PA Wyeth, Madison, NJ, 07940 (U.S. individual)
PI US 2003032626 A1 20030213
AI US 2002-171041 A1 20020613 (10)
PRAI US 2001-299651P 20010620 (60)
DT Utility
FS APPLICATION
LREP Wyeth, 5 Giralda Farms, Madison, NJ, 07940

CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1368
AB This invention provides PAI-1 inhibiting compounds of Formula I:
##STR1##

wherein: R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are eachH, alkyl,, alkanoyl, halo, OH, aryl optionally substituted with R.sub.8, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; R.sub.5 is H, alkyl, perfluoroalkyl, aryl optionally substituted with R.sub.8, alkanoyl, aroyl optionally substituted with R.sub.8; R.sub.6 is H, alkyl, alkylaryl, benzyl optionally substituted with R.sub.8, alkanoyl, aroyl optionally substituted with R.sub.8; R.sub.7 is H, alkyl, alkylaryl, aryl optionally substituted with R.sub.8; n is 0-6; A is COOH, or an acid mimic such as tetraazole, SO.sub.3H, PO.sub.3H.sub.2, tetronic acid, etc.; R.sub.8 is H, alkyl, cycloalkyl, alkanoyl, halo, OH, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; or a **pharmaceutically** acceptable salt thereof; as well as **pharmaceutical** compositions and methods of treatment using these compounds.

L9 ANSWER 6 OF 267 USPATFULL
AN 2003:40373 USPATFULL
TI Low fluorescence assay platforms and related methods for drug discovery
IN Coassin, Peter J., Encinitas, CA, United States
Harootunian, Alec Tate, Del Mar, CA, United States
Pham, Andrew A., Del Mar, CA, United States
Stylli, Harry, San Diego, CA, United States
Tsien, Roger Y., La Jolla, CA, United States
PA Aurora Biosciences Corporation, San Diego, CA, United States (U.S. corporation)
PI US 6517781 B1 20030211
AI US 2000-476959 20000103 (9)
RLI Continuation of Ser. No. US 1998-30578, filed on 24 Feb 1998, now patented, Pat. No. US 6171780 Continuation-in-part of Ser. No. US 1997-868049, filed on 3 Jun 1997, now patented, Pat. No. US 5910287 Continuation-in-part of Ser. No. US 1997-867584, filed on 2 Jun 1997 Continuation-in-part of Ser. No. US 1997-868018, filed on 3 Jun 1997 Continuation-in-part of Ser. No. US 1997-867567, filed on 2 Jun 1997
DT Utility
FS GRANTED
EXNAM Primary Examiner: Warden, Jill; Assistant Examiner: Handy, Dwayne K
LREP Gray, Cary, Ware & Friedenrich LLP, Haile, Lisa A.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 2383
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB One aspect of the present invention is a multi-well platform for fluorescence measurements, comprising a plurality of wells within a frame, wherein the multi-well platform has low fluorescence background. Another aspect of the present invention is a system for spectroscopic measurements, comprising reagents for an assay and a multi-well platform for fluorescence measurements. A further aspect of the present invention is a method for detecting the presence of an analyte in a sample contained in a multi-well platform by detecting light emitted from the sample. Another aspect of the present invention is a method from identifying a modulator of a biological process or target in a sample contained in a multi-well platform by detecting light emitted from the sample. Another aspect of the present invention is a **composition** identified by this method. A further aspect of the present invention is a method to identify a **therapeutic**. A further aspect of the present invention is a method of testing a **therapeutic** for **therapeutic** activity and toxicology by identifying a

therapeutic using a method of the present invention and monitoring the toxicology and efficacy of the **therapeutic** in an in vivo model.

L9 ANSWER 7 OF 267 USPATFULL
AN 2003:37593 USPATFULL
TI Optical molecular sensors for cytochrome P450 activity
IN Makings, Lewis R., Encinitas, CA, UNITED STATES
Zlokarnik, Gregor, La Jolla, CA, UNITED STATES
PI US 2003027238 A1 20030206
AI US 2001-995961 A1 20011127 (9)
RLI Continuation of Ser. No. US 1999-301525, filed on 28 Apr 1999, PENDING
PRAI US 1998-112252P 19981214 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2790
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods of using a compound as an optical probe or sensor of the activity of at least one cytochrome P450 enzyme, and methods of using the compound to screen candidate drugs, and kits for performing these methods. The optical probe of the invention is a compound having the generic structure Y-L-Q, wherein Y is selected from the group consisting of Q as herein defined, saturated C.sub.1-C.sub.20 alkyl, unsaturated C.sub.1-C.sub.20 alkenyl, unsaturated C.sub.1-C.sub.20 alkynyl, substituted saturated C.sub.1-C.sub.20 alkyl, substituted unsaturated C.sub.1-C.sub.20 alkenyl, substituted unsaturated C.sub.1-C.sub.20 alkynyl, C.sub.1-C.sub.20 cycloalkyl, C.sub.1-C.sub.20 cycloalkenyl, substituted saturated C.sub.1-C.sub.20 cycloalkyl, substituted unsaturated C.sub.1-C.sub.20 cycloalkenyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; L is selected from the group of (--OCR.sup.2H).sub.p--, wherein for each p, all R.sup.2 are separately selected from the group consisting of a hydrogen atom, saturated C.sub.1-C.sub.20 alkyl, unsaturated C.sub.1-C.sub.20 alkenyl, unsaturated C.sub.1-C.sub.20 alkynyl, substituted saturated C.sub.1-C.sub.20 alkyl, substituted unsaturated C.sub.1-C.sub.20 alkenyl, substituted unsaturated C.sub.1-C.sub.20 alkynyl, C.sub.1-C.sub.20 cycloalkyl, C.sub.1-C.sub.20 cycloalkenyl, substituted saturated C.sub.1-C.sub.20 cycloalkyl, substituted unsaturated C.sub.1-C.sub.20 cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and p is a positive integer no greater than twelve; and Q is a chemical moiety that gives rise to optical properties in its hydroxy or hyrdoxylate, phenol or phenoxide form that are different from the optical properties that arise from its ether form. Most preferably, p is one, R.sup.2 is hydrogen, and Q is the ether form of a phenoxide fluorophore.

L9 ANSWER 8 OF 267 USPATFULL
AN 2003:33292 USPATFULL
TI Optical molecular sensors for cytochrome P450 activity
IN Makings, Lewis R., Encinitas, CA, United States
Zlokarnik, Gregor, La Jolla, CA, United States
PA Vertex Pharmaceuticals (San Diego), LLC, San Diego, CA, United States (U.S. corporation)
PI US 6514687 B1 20030204
AI US 1999-458927 19991210 (9)
RLI Continuation-in-part of Ser. No. US 1999-301525, filed on 28 Apr 1999
PRAI US 1998-112252P 19981214 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Fredman, Jeffrey; Assistant Examiner: Maupin,

Christine
LREP Knobbe Martens Olson & Bear LLP
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 3297
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a compound, useful as an optical probe or sensor of the activity of at least one cytochrome P450 enzyme, and methods of using the compound to screen candidate drugs, and candidate drugs identified by these methods. The optical probe of the invention is a compound having the generic structure Y--L--Q, wherein Y is selected from the group consisting of Q as herein defined, saturated C.sub.1-C.sub.20 alkyl, unsaturated C.sub.1-C.sub.20 alkenyl, unsaturated C.sub.1-C.sub.20 alkynyl, substituted saturated C.sub.1-C.sub.20 alkyl, substituted unsaturated C.sub.1-C.sub.20 alkenyl, substituted unsaturated C.sub.1-C.sub.20 alkynyl, C.sub.1-C.sub.20 cycloalkyl, C.sub.1-C.sub.20 cycloalkenyl, substituted saturated C.sub.1-C.sub.20 cycloalkyl, substituted unsaturated C.sub.1-C.sub.20 cycloalkenyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; L is selected from the group of (--OCR.sup.2H).sub.p--, wherein for each p, all R.sup.2 are separately selected from the group consisting of a hydrogen atom, saturated C.sub.1-C.sub.20 alkyl, unsaturated C.sub.1-C.sub.20 alkenyl, unsaturated C.sub.1-C.sub.20 alkynyl, substituted saturated C.sub.1-C.sub.20 alkyl, substituted unsaturated C.sub.1-C.sub.20 alkenyl, substituted unsaturated C.sub.1-C.sub.20 alkynyl, C.sub.1-C.sub.20 cycloalkyl, C.sub.1-C.sub.20 cycloalkenyl, substituted saturated C.sub.1-C.sub.20 cycloalkyl, substituted unsaturated C.sub.1-C.sub.20 cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and p is a positive integer no greater than twelve; and Q is a chemical moiety that gives rise to optical properties in its hydroxy or hyrdoxylate, phenol or phenoxide form that are different from the optical properties that arise from its ether form. Most preferably, p is one, R.sup.2 is hydrogen, and Q is the ether form of a phenoxide fluorophore.

L9 ANSWER 9 OF 267 USPATFULL
AN 2003:30949 USPATFULL
TI Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
IN Burke, James R., Holland, PA, UNITED STATES
Townsend, Robert M., Boothwyn, PA, UNITED STATES
Qiu, Yuping, Windsor, CT, UNITED STATES
Zusi, Fred Christopher, Hamden, CT, UNITED STATES
Nadler, Steven G., Boothwyn, PA, UNITED STATES
PI US 2003022898 A1 20030130
AI US 2002-62847 A1 20020201 (10)
RLI Continuation-in-part of Ser. No. US 2001-965977, filed on 27 Sep 2001, PENDING
PRAI US 2000-223304P 20001003 (60)
US 2001-265853P 20010201 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of I.kappa.B kinase (IKK). Also described are IKK inhibitors effective for the prevention and treatment of inflammatory and immune-related

diseases or disorders, as demonstrated in vivo. Further embodiments of the present invention relate to a specific IKK inhibitors, 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline and compounds of formula (I), salts thereof, and **pharmaceutical** compositions.

L9 ANSWER 10 OF 267 USPATFULL
AN 2003:30941 USPATFULL
TI Heterocyclic dihydropyrimidine compounds
IN Atwal, Karnail S., Newtown, PA, UNITED STATES
Vaccaro, Wayne, Yardley, PA, UNITED STATES
Lloyd, John, Yardley, PA, UNITED STATES
Finlay, Heather, Lawrenceville, NJ, UNITED STATES
Yan, Lin, Princeton, NJ, UNITED STATES
Bhandaru, Rao S., Belle Mead, NJ, UNITED STATES
PI US 2003022890 A1 20030130
AI US 2000-729731 A1 20001205 (9)
PRAI US 2000-236037P 20000928 (60)
US 1999-169091P 19991206 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7238
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the K.sub.v1 subfamily of voltage gated K.sup.+ channels, especially inhibitors K.sub.v1.5 which has been linked to the ultra-rapidly activating delayed rectifier K.sup.+ current I.sub.Kur), methods of using such compounds in the prevention and treatment of arrhythmia and I.sub.Kur-associated conditions, and **pharmaceutical** compositions containing such compounds.

=> d l19 11-30 bib ab

L19 ANSWER 11 OF 30 USPATFULL
AN 2001:163218 USPATFULL
TI N-linked sulfonamides of heterocyclic thioesters
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jai-He, Cockeysville, MD, United States
Huang, Wei, Baltimore, MD, United States
PA GPI Nil Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6294551 B1 20010925
AI US 2000-516239 20000301 (9)
RLI Division of Ser. No. US 1997-996342, filed on 22 Dec 1997, now patented, Pat. No. US 6121273 Continuation-in-part of Ser. No. US 1996-775584, filed on 31 Dec 1996, now patented, Pat. No. US 5874449, issued on 23 Feb 1999
DT Utility
FS GRANTED
EXNAM Primary Examiner: Oswecki, Jane C.
LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua B.
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule N-linked sulfonamides of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the

enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 12 OF 30 USPATFULL
AN 2001:158332 USPATFULL
TI Small molecule inhibitors of rotamase enzyme activity
IN Hamilton, Gregory S., Catonsville, MD, United States
Steiner, Joseph P., Hampstead, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6291510 B1 20010918
AI US 1998-73962 19980507 (9)
RLI Continuation-in-part of Ser. No. US 1996-693003, filed on 6 Aug 1996 Continuation of Ser. No. US 1995-479436, filed on 7 Jun 1995, now patented, Pat. No. US 5614547
DT Utility
FS GRANTED
EXNAM Primary Examiner: Gerstl, Robert
LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua L.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

L19 ANSWER 13 OF 30 USPATFULL
AN 2001:131322 USPATFULL
TI N-linked ureas and carbamates of heterocyclic thioesters
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States
Huang, Wei, Chesterfield, MO, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6274607 B1 20010814
AI US 1999-393650 19990910 (9)
RLI Division of Ser. No. US 1997-997451, filed on 23 Dec 1997, now patented, Pat. No. US 5958949 Continuation-in-part of Ser. No. US 1996-775585, filed on 31 Dec 1996, now patented, Pat. No. US 5935989
DT Utility
FS GRANTED
EXNAM Primary Examiner: Higel, Floyd D.; Assistant Examiner: Sackey, Ebenezer
LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua B.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 14 OF 30 USPATFULL
AN 2001:97914 USPATFULL
TI N-oxides of heterocyclic esters, amides, thioesters, and ketones
IN Hamilton, Gregory S., Catonsville, MD, United States
Steiner, Joseph P., Hampstead, MD, United States
Burak, Eric S., Forest Hill, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6251892 B1 20010626
AI US 2000-556482 20000421 (9)
RLI Continuation of Ser. No. US 1998-112319, filed on 9 Jul 1998, now

patented, Pat. No. US 6054542 Continuation of Ser. No. US 1997-807406, filed on 28 Feb 1997, now patented, Pat. No. US 5846979, issued on 8 Dec 1998
DT Utility
FS GRANTED
EXNAM Primary Examiner: Seaman, D. Margaret
LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua B.
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule N-oxides of heterocyclic esters, amides, thioesters, and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 15 OF 30 USPATFULL
AN 2001:82793 USPATFULL
TI Carbamate and urea compositions and neurotrophic uses
IN Li, Jia-He, 27 Manor Ct., Cockeysville, MD, United States 21030
Steiner, Joseph P., 988 Sugar Maple St., Hampstead, MD, United States 21074
Hamilton, Gregory S., 6501 Frederick Rd., Catonsville, MD, United States 21228
PI US 6242468 B1 20010605
AI US 1998-139672 19980825 (9)
RLI Continuation-in-part of Ser. No. US 1997-805646, filed on 27 Feb 1997
DT Utility
FS Granted
EXNAM Primary Examiner: Criares, Theodore J.
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to **pharmaceutical** compositions and methods for effecting a neuronal activity using low molecular weight, small molecule carbamates and ureas having an affinity for FKBP-type immunophilins.

L19 ANSWER 16 OF 30 USPATFULL
AN 2001:56120 USPATFULL
TI Heterocyclic esters and amides
IN Li, Jia-He, Cockeysville, MD, United States
Hamilton, Gregory S., Catonsville, MD, United States
PA Gpi Nil Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6218544 B1 20010417
AI US 1999-442628 19991118 (9)
RLI Division of Ser. No. US 1998-27622, filed on 23 Feb 1998 Division of Ser. No. US 1996-719947, filed on 25 Sep 1996, now patented, Pat. No. US 5801187, issued on 1 Sep 1998
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.
LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua B.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1052
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule heterocyclic esters and amides having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity

associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 17 OF 30 USPATFULL
AN 2001:36819 USPATFULL
TI Heterocyclic esters and amides
IN Li, Jia-He, Cockeysville, MD, United States
Hamilton, Gregory S., Catonsville, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6200972 B1 20010313
AI US 1998-27622 19980223 (9)
RLI Division of Ser. No. US 1996-719947, filed on 25 Sep 1996, now patented, Pat. No. US 5801187
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.
LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua B.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1158
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule heterocyclic esters and amides having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 18 OF 30 USPATFULL
AN 2001:18489 USPATFULL
TI N-linked ureas and carbamates of heterocyclic thioesters
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States
Huang, Wei, Baltimore, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6184243 B1 20010206
AI US 1998-165372 19981002 (9)
RLI Division of Ser. No. US 1996-775585, filed on 31 Dec 1996, now patented, Pat. No. US 5935989
DT Utility
FS Granted
EXNAM Primary Examiner: McKane, Joseph K.; Assistant Examiner: Sackey, Ebenezer
LREP Nath & Associates, Nath, Gary M., Juneau, Todd L.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 19 OF 30 USPATFULL
AN 2000:174804 USPATFULL
TI Telomerase catalytic subunit
IN Cech, Thomas R., Boulder, CO, United States
Lingner, Joachim, Boulder, CO, United States
PA University Technology Corporation, Boulder, CO, United States (U.S. corporation)
Geron Corporation, Menlo Park, CA, United States (U.S. corporation)
PI US 6166178 20001226
AI US 1997-974549 19971119 (8)

RLI Continuation-in-part of Ser. No. US 1997-915503, filed on 14 Aug 1997, now abandoned And a continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997 And a continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997 which is a continuation-in-part of Ser. No. US 1997-854050, filed on 9 May 1997 which is a continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997 which is a continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997 which is a continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-724643, filed on 1 Oct 1996
PRAI WO 1997-US17618 19971001
WO 1997-US17885 19971001
DT Utility
FS Granted
EXNAM Primary Examiner: Eyler, Yvonne
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 128 Drawing Figure(s); 103 Drawing Page(s)
LN.CNT 23874
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods related to telomerase reverse transcriptase, the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

L19 ANSWER 20 OF 30 USPATFULL
AN 2000:125050 USPATFULL
TI N-linked sulfonamides of heterocyclic thioesters
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jai-He, Cockeysville, MD, United States
Huang, Wei, Baltimore, MD, United States
PA GPI NIL Holdings, Inc, Wilmington, DE, United States (U.S. corporation)
PI US 6121273 20000919
AI US 1997-996342 19971222 (8)
RLI Continuation-in-part of Ser. No. US 1996-775584, filed on 31 Dec 1996, now patented, Pat. No. US 5874449
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Oswecki, Jane C.
LREP Nath & Associates, PLLC, Nath, Gary M., Juneau, Todd L.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule N-linked sulfonamides of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 21 OF 30 USPATFULL
AN 2000:50702 USPATFULL
TI N-oxides of heterocyclic esters, amides, thioesters, and ketones
IN Hamilton, Gregory S., Catonsville, MD, United States
Steiner, Joseph P., Hampstead, MD, United States
Burak, Eric S., Forest Hill, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6054452 20000425
AI US 1998-112319 19980709 (9)
RLI Continuation of Ser. No. US 1997-807406, filed on 28 Feb 1997, now

patented, Pat. No. US 8846979
DT Utility
FS Granted
EXNAM Primary Examiner: Seaman, D. Margaret
LREP Nath & Associates, Nath, Gary M., Juneau, Todd L.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 940
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule N-oxides of heterocyclic esters, amides, thioesters, and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 22 OF 30 USPATFULL
AN 1999:151234 USPATFULL
TI Heterocyclic thioesters and ketones
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States
PA Gpi Nil Holdings Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5990131 19991123
AI US 1997-904461 19970801 (8)
RLI Continuation-in-part of Ser. No. US 1996-721765, filed on 25 Sep 1996
DT Utility
FS Granted
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Aulakh, Charanjit S.
LREP Nath & Associates, Nath, Gary M., Heiman, Lee C.
CLMN Number of Claims: 58
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1779
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule heterocyclic thioesters and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 23 OF 30 USPATFULL
AN 1999:117520 USPATFULL
TI N-linked ureas and carbamates of piperidyl thioesters
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States
Huang, Wei, Chesterfield, MO, United States
PA GPI NIL Holdings Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5958949 19990928
AI US 1997-997451 19971223 (8)
RLI Continuation-in-part of Ser. No. US 1996-775585, filed on 31 Dec 1996
DT Utility
FS Granted
EXNAM Primary Examiner: Ramsuel, Robert W.; Assistant Examiner: Sackey, Ebenezer
LREP Nath & Associates, Nath, Gary M., Juneau, Todd L.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1793
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 24 OF 30 USPATFULL
AN 1999:92704 USPATFULL
TI N-linked ureas and carbamates of heterocyclic thioesters
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States
Huang, Wei, Baltimore, MD, United States
PA GPI NIL Holdings Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5935989 19990810
AI US 1996-775585 19961231 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Sackey, Ebenezer
LREP Nath, Gary M., Juneau, Todd L.Nath & Associates
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1206
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 25 OF 30 USPATFULL
AN 1999:24667 USPATFULL
TI N-linked sulfonamides of heterocyclic thioesters
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States
Huang, Wei, Baltimore, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5874449 19990223
AI US 1996-775584 19961231 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Oswecki, Jane C.
LREP Nath, Gary M., Juneau, Todd L.Nath & Associates
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1340
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule N-linked sulfonamides of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 26 OF 30 USPATFULL
AN 1999:4688 USPATFULL
TI Small molecule inhibitors of rotamase enzyme activity
IN Hamilton, Gregory S., Catonsville, MD, United States
Steiner, Joseph P., Hampstead, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5859031 19990112
AI US 1996-650461 19960521 (8)
RLI Continuation-in-part of Ser. No. US 1995-479436, filed on 7 Jun 1995, now patented, Pat. No. US 5614547
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Nath, Gary M., Juneau, Todd L.Nath & Associates
CLMN Number of Claims: 19
ECL Exemplary Claim: 1

DRWN 26 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 1761
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic N-glyoxyl-prolyl ester compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

L19 ANSWER 27 OF 30 USPATFULL
AN 1998:154286 USPATFULL
TI N-oxides of heterocyclic esters, amides, thioesters, and ketones
IN Hamilton, Gregory S., Catonsville, MD, United States
Steiner, Joseph P., Hampstead, MD, United States
Burak, Eric S., Forest Hill, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5846979 19981208
AI US 1997-807406 19970228 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Mach, D. Margaret M.
LREP Nath, Gary M., Juneau, Todd L.Nath & Associates
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1310
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule N-oxides of heterocyclic esters, amides, thioesters, and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 28 OF 30 USPATFULL
AN 1998:104757 USPATFULL
TI Heterocyclic esters and amides
IN Li, Jia-He, Cockoysville, MD, United States
Hamilton, Gregory S., Catonsville, MD, United States
PA GPI-NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5801187 19980901
AI US 1996-719947 19960925 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Aulakh, Charanjit S.
LREP Nath, Gary M., Juneau, Todd I.Nath & Associates
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 820
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule heterocyclic esters and amides having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 29 OF 30 USPATFULL
AN 1998:88862 USPATFULL
TI Heterocyclic thioesters
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States
PA GPI Nil Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5786378 19980728

AI US 1996-721765 19960925 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Aulakh, Charanjit S.
LREP Nath, Gary M., Juneau, Todd L.Nath & Associates
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1256
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic low molecular weight, small molecule heterocyclic thioesters and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 30 OF 30 USPATFULL
AN 97:25061 USPATFULL
TI Small molecule inhibitors of rotamase enzyme
IN Hamilton, Gregory S., Catonsville, MD, United States
Steiner, Joseph P., Hampstead, MD, United States
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI US 5614547 19970325
AI US 1995-479436 19950607 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Nath, Gary M.Nath & Associates
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1116
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to neurotrophic compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 17:02:52 ON 07 MAR 2003